BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 14524061)

  • 1. [For each diabetic the right program. Insulin therapy according to the physiology model].
    Bischoff A
    MMW Fortschr Med; 2003 Aug; 145(31-32):10. PubMed ID: 14524061
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing glycemic control with insulin glargine.
    Williams JB
    Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advantages of fast-acting insulin analogs: preprandial greater HbA1c lowering -- postprandial lower weight].
    MMW Fortschr Med; 2005 Aug; 147(33-34):45. PubMed ID: 16138637
    [No Abstract]   [Full Text] [Related]  

  • 4. [A year after the introduction. Generic human insulin tested].
    MMW Fortschr Med; 2002 Feb; 144(8):50. PubMed ID: 11910825
    [No Abstract]   [Full Text] [Related]  

  • 5. [American Diabetes Association's Annual Meeting: new data on insulin glargine: early combination promises more success].
    MMW Fortschr Med; 2005 Aug; 147(33-34):44-5. PubMed ID: 16138636
    [No Abstract]   [Full Text] [Related]  

  • 6. [An update on multiple insulin injection therapy in type 1 and 2 diabetes].
    Varanauskiene E; Varanauskaite I; Ceponis J
    Medicina (Kaunas); 2006; 42(9):770-9. PubMed ID: 17028476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Start of insulin therapy. How to ensure patient compliance?].
    MMW Fortschr Med; 2006 Aug; 148(35-36):12-3. PubMed ID: 16995354
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical experiences with Lantus therapy in Swedish routine health care].
    Löndahl M; Nilsson A; Katzman P
    Lakartidningen; 2005 Sep 5-11; 102(36):2503, 2505. PubMed ID: 16196437
    [No Abstract]   [Full Text] [Related]  

  • 9. [New fast-acting insulin analog. This insulin profits type l and type 2 diabetics].
    Wepner U
    MMW Fortschr Med; 2004 Nov; 146(47):62-3. PubMed ID: 15624662
    [No Abstract]   [Full Text] [Related]  

  • 10. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
    Philis-Tsimikas A; Zhang Q; Walker C
    Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glargine clinical trials.
    White JR
    Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
    [No Abstract]   [Full Text] [Related]  

  • 12. Does a patient-administered titration algorithm of insulin glargine improve glycemic control?
    Edelman S
    Nat Clin Pract Endocrinol Metab; 2006 Feb; 2(2):78-9. PubMed ID: 16932261
    [No Abstract]   [Full Text] [Related]  

  • 13. Insulin glargine in the treatment of type 1 and type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasting and insulin glargine in individuals with type 1 diabetes.
    Mucha GT; Merkel S; Thomas W; Bantle JP
    Diabetes Care; 2004 May; 27(5):1209-10. PubMed ID: 15111549
    [No Abstract]   [Full Text] [Related]  

  • 15. Ultra-long-acting insulins for a lifestyle-related pandemic.
    Kudva YC; Basu A
    Lancet; 2011 Mar; 377(9769):880-1. PubMed ID: 21396704
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fasting capillary glucose variability between insulin glargine and NPH.
    Mu P; Lu H; Zhang G; Chen Y; Fu J; Wang M; Shu J; Zeng L
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e4-7. PubMed ID: 20970870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Jan; 8():3. PubMed ID: 19152692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: transition to target study.
    Shomali ME; Herr DL; Hill PC; Pehlivanova M; Sharretts JM; Magee MF
    Diabetes Technol Ther; 2011 Feb; 13(2):121-6. PubMed ID: 21284478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
    Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.